The latest price trends of dacomitinib/dacomitinib in 2025

Dacomitinib/Dacomitinib (Dacomitinib), as an oral targeted drug for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer, has been officially approved for marketing in China and has been included in the National Medical Insurance List as a Class B drug. The original product of this drug was developed by Pfizer, and its trade name is "Vita". Its price has dropped significantly after medical insurance negotiations, which has reduced the financial burden on patients, especially in the context of long-term medication, making it more accessible.

In the domestic market, the medical insurance payment price of dacomitinib is closely related to its specifications. Taking the commonly used 15mg*30 tablets as an example, the current price per box is about more than 1,000 yuan, and the patient’s out-of-pocket payment after paying for medical insurance is significantly reduced, making this drug one of the more economical EGFR-TKI options. It should be noted that the medical insurance reimbursement ratio and self-payment ratio may vary according to local policies and hospital levels. Patients should make specific calculations based on local medical insurance regulations.

In overseas markets, the price of dacomitinib has fluctuated significantly, especially in the EU, the United States and other countries, where the price of the original drug is still relatively high. For example, the price of the European version30 tablets of 45mg may be as high as about 20,000 yuan. Due to the impact of exchange rates and import channels, patients need to bear the full cost. In addition, some pharmaceutical companies in developing countries have also launched generic versions of dacomitinib. These products usually have the same active ingredients and bioequivalence as the original drug. Taking the Lao pharmaceutical factory as an example, the price of its 45 mg 30 tablets of generic drugs may be only about 800 yuan, making it an option for some patients who are not covered by medical insurance or have limited financial conditions.

Although the price of generic drugs is more advantageous, patients must pay attention to the legality and safety of the source of drugs when choosing overseas channels to avoid purchasing counterfeit drugs or improper storage and transportation that may affect the therapeutic effect.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro